In conclusion, this study shows that the prediction models combining the expression of PD-L1 and CD4+/CD8+ TILs as well as CD163+ TAMs can accurately distinguish GC patients with substantially different DFS and OS. This evidence concerns the gene CD163 and gastric cancer.